Pharmafile Logo

Amgen

- PMLiVE

AbbVie reaches agreement for affordable prescription drugs with US government

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

- PMLiVE

BMS announces affordable drug price agreement with US government

The company will provide Eliquis, its oral blood thinner, free of charge to Medicaid

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

Gilead agrees on affordable medicines plan with US government

The company recently announced a $32bn investment in US R&D and manufacturing

- PMLiVE

Novartis agrees to lower drug prices in deal with US government

In 2025, the pharma company announced a $23bn US investment commitment

- PMLiVE

Lilly announces plans for $6bn US manufacture facility

The site is the third of four new US sites that Lilly has announced

- PMLiVE

AstraZeneca announces $2bn investment in US manufacturing

The new and expanded facilities will support production of rare disease drug treatments

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Novo Nordisk agrees to lower certain drug prices in the US

The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

- PMLiVE

Lilly announces agreement with US government to lower patient costs

The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

- PMLiVE

AstraZeneca to invest $4.5bn in US manufacturing facility

The investment will further support the company’s growing oncology pipeline

- PMLiVE

AstraZeneca announces agreement with US government to reduce medicine costs

The pharma company is the latest to offer direct-to-consumer purchasing

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links